INTERPRETING RESULTS FROM BAYESIAN NETWORK META-ANALYSES (NMA): A GUIDE FOR NON-STATISTICIANS

Illustrative Example
The interpretation of results from Bayesian NMAs is not standardized. In the context of an HTA submission, interpretation of findings may vary across HTA bodies.
[1] NICE DSU (Decision Support Unit). Evidence Synthesis TSD (Technical Support Documents) Series. 
Key concepts behind Bayesian statistics
• Fig • Objective: to compare A vs B, C and D, using a Bayesian NMA based on the odds-ratio (OR), following the methodological approach recommended by NICE • E.g. the relative treatment effect for response rate.
• OR A vs. B >1 indicates a higher response rate in favour of treatment A.
• The DIC (Deviance Information Criterion) is commonly used to select fixed vs. random effects model • DIC represents a trade-off between model adequacy and complexity (i.e. complex models, for example a random effect vs a fixed effect model, are penalised)
• The model associated with the lowest DIC is selected, considering a 3 to 5-point difference in DIC to be meaningful for model selection.
• Table 1) 95% Credibility interval (CrI): there is 95% probability that the parameter lies in the credibility interval. The credibility interval is estimated based on the percentiles of the posterior distribution (Fig. 2) .
Vague / non-informative prior distribution: a priori knowledge that is vague enough not to influence the results. Using a vague (or non-informative)
prior distribution leads to results driven by the data only. All NMA guidelines recommend using vague prior distributions.
Fixed / random effects model: the fixed effect models assume a same underlying unknown true treatment effect across all studies and are used under the assumption of no heterogeneity between studies. Random effects models assume that treatment effects are drawn from a common distribution and are used under the assumption of unexplained heterogeneity between studies, i.e. treatment effect allowed to vary between studies.
SUCRA (Surface Under the Cumulative Ranking): parameter used to rank treatments based on their probability of ranking 1 st , 2 nd , etc. The SUCRA ranges between 0% (i.e. the treatment always ranks last) to 100% (i.e. the treatment always ranks first).
Results from the NMA can be presented according to the following templates.
• Table 1 : Results of the NMA presenting the median of the OR, the 95% CrI and the Bayesian pairwise probability (P)
Bayesian pairwise probability (P): Probability for a treatment to perform better than a comparator, i.e. probability of the OR to be higher than 1. The threshold to demonstrate that a treatment is more effective than another is not standardized • Analogy with the frequentist approach: A treatment is more effective than another if the 95% CrI excludes the value 1 (in case of a ratio). This is equivalent to a Bayesian pairwise probability P>97.5%
• Authors have reported in the context of an NMA in the respiratory area that 85%<P<97.5% can be interpreted as "likely to be favourable" (although no recommended in guidelines) [ • Interpretation for treatment A: there is a 60% probability that A ranks 1 st , a 90% probability that A ranks 1 st or 2 nd and a 100% probability that A ranks 1, 2 nd or 3 rd . The SUCRA for A is the area under the curve, i.e. 83%.
